Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis

Multiple Sclerosis

Volumn 6, Issue 2, 2000, Pages 69-77

  Rohowsky Kochan, C ^a   Molinaro, D ^a   Cook, S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Autoantigen specific T cells; Multiple sclerosis; Th1 Th2 cytokines

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; MESSENGER RNA; MYELIN BASIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; LYMPHOCYTE CLONE; MALE; MULTIPLE SCLEROSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 0033998708     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245850000600203     Document Type: Article

References (53)

1. Mosmann TR et al. (1986) Two types of murine helper T cell clone. I. Detinition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357.
2. Chu DJ, Mosmann TR. (1987) Two types of murine helper T cell clone. II. Delayed type hypersensitivity is mediated by Th1 clones. J Immunol 138: 3688-3694.
3. Firestein GS et al. (1989) A new murine CD4+ T cell subset with an unrestricted cytokine profile. J Immunol 143: 518-525.
4. Del Prete G et al. (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150: 353-360.
5. + T cell clones and peripheral blood T cells. J Immunol 149: 2378-2384.
6. Mosmann TR, Sad S. (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146.
7. Romagnani S. (1994) Lymphokine production by human T cells in disease states. Annu Rev Immunol 12: 227-257.
8. Ben-Nun A, Wekerle M, Cohen IR. (1981) The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11: 195-199.
9. Yamamura T et al. (1986) Experimental allergic encephalomyelitis induced by protolipid apoprotein in Lewis rats. J Neuroimmunol 12: 143-153.
10. Zamvil SS et al. (1985) Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med 162: 2107-2124.
11. Zamvil SS et al. (1988) Predominant expression of a T cell receptor Vβ gene subfamily in autoimmune encephalomyelitis. J Exp Med 167: 1586-1596.
12. Urban JL et al. (1988) Restricted use of T-cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 54: 577-592.
13. Baron JL et al. (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177: 57-68.
14. Merrill JE et al. (1992) Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc Natl Acad Sci USA 89: 574-578.
15. Kennedy MK, Torrance DS, Picha KS, Mohler KM. (1992) Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149: 2496-2505.
16. Khoury SJ, Hancock WW, Weiner HL. (1992) Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 176: 1355-1364.
17. Leonard JP, Waldburger KE, Goldman SJ. (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 181: 381-386.
18. Racke MK et al. (1994) Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180: 1961-1966.
19. Panitch HS, Hirsch RL, Haley AS, Johnson KP. (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet i: 893-895.
20. Beck J et al. (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand 78: 318-323.
21. Woodroofe MN, Cuzner ML. (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 5: 583-588.
22. Selmaj KW, Raine CS, Cannella B, Brosnan CF. (1991) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87: 949-954.
23. Cannella B, Raine CS. (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37: 424-435.
24. Selmaj KW, Raine CS. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-346.
25. Link J et al. (1994) Increased transforming growth factor-β, interleukin-4 and interferon-γ in multiple sclerosis. Ann Neurol 36: 379-386.
26. Riekmann P et al. (1994) Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 44: 1523-1526.
27. Fukaura H et al. (1996) Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 98: 70-77.
28. Chen Y et al. (1994) Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelilis. Science 265: 1237-1240.
29. Rudick RA et al. (1996) Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 40: 618-627.
30. Rep MHG, Hintzen RQ, Polman CH, van Lier RAW. (1996) Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 67: 111-118.
31. Richert JR, Reuben-Burnside CA, Diebler G, Kies MW. (1988) Peptide specificities of myelin basic protein-reactive human T-cell clones. Neurology 38: 739-742.
32. Martin R et al. (1990) Fine specificity and HLA restriction of myelin basic protein specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 145: 540-548.
33. Ota K et al. (1990) T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346: 183-187.
34. Wucherpfennig KW et al. (1990) Shared human T cell receptor Vβ usage to immunodominant regions of myelin basic protein. Science 248: 1016-1019.
35. Ben-Nun A et al. (1990) Restricted T-cell receptor Vβ gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: Predominant genes vary in individuals. Proc Natl Acad Sci USA 88: 2466-2470.
36. Kotzin BL et al. (1991) Preterential T-cell receptor β-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci USA 88: 9161-9165.
37. Rohowsky-Kochan C et al. (1994) Induction of autologous mixed lymphocyte culture responses by myelin basic protein-reactive T cell clones. J Neuroimmunol 50: 59-70.
38. Chomczymski P, Sacchi N. (1987) Single step method of RNA isolation by acid guanidinium thiocyinate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
39. Hemmer B et al. (1996) Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). J Neurosci Res 45: 852-862.
40. Hermans G et al. (1997) Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol 42: 18-27.
41. Voskuhl RR et al. (1993) T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 15: 137-143.
42. Vandevyver C et al. (1998) Cytokine mRNA profile of myelin basic protein reactive T-cell clones in patients with multiple sclerosis. Autoimmunity 28: 77-89.
43. Correale J et al. (1995) Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 154: 2959-2968.
44. 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 88: 2918-2921.
45. 1. J Immunol 146: 3012-3017.
46. Johns LD, Flanders KC, Ranges GE, Sriram S. (1991) Successful treatment of experimental allergic encephalomyelitis with transforming growth factor. J Immunol 147: 1792-1796.
47. Gerosa F et al. (1996) Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-γ and interleukin-10. J Exp Med 183: 2559-2569.
48. Windhagen A et al. (1996) IL-12 induces human T cells secreting IL-10 with IFN-γ. J Immunol 157: 1127-1131.
49. h 1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN-γ or IL-2 determines their function. Int Immunol 7: 1287-1294.
50. Cohen SBA et al. (1995) High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthrit Rheumat 38: 946-952.
51. Nicholson LB et al. (1995) An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3: 397-405.
52. Pohl-Koppe A et al. (1998) Identification of a T cell subset capable of both IFN-γ and IL-10 secretion in patients with chronic Borrelia burgdorferi infection. J Immunol 160: 1804-1810.
53. R): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 92: 113-121.